“This is a huge disappointment in my career”
Jan van de Winkel, CEO in Genmab, is deeply disappointed with the failed phase III study with cancer drug Arzerra, but his belief in the drug is unwavering. Even the world’s second best selling drug has failed in a slew of studies, he points out.
by Benjamin Werner Christensen
It has happened before and it will happen again; even the best of drugs fail in phase III studies from time to time. The disappointing results data on cancer drug Arzerra were not what the company had expected, but CEO Jan van de Winkel looks ahead with optimism.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
